CClinicalTrials.gg
CompletedNCT03449576Updated Jul 24, 2024Results posted

Efficacy and Neural Mediators of Response to Trauma Management Therapy for PTSD

An interventional study of Trauma Management Therapy and Exposure Therapy with Psychotherapy group in PTSD, sponsored by VA Office of Research and Development. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2024-07-24.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Social difficulties are serious and frequent complicating factors in the treatment of post-traumatic stress disorder (PTSD). To better understand how treatment of post-traumatic stress disorder impacts neural mechanisms of social cognition, the investigators are examining behavior and brain processes associated with response to Trauma Management Therapy. Understanding the behavioral and neural impact of psychotherapy may contribute to development of more effective treatments for PTSD.

Read the detailed description

PTSD is associated with significant interpersonal difficulties that interfere with functioning. As such, this work is intended to evaluate the empirical support for a novel treatment that fills a significant gap in the treatment options available to Veterans with PTSD who suffer with interpersonal difficulties. In this study the investigators will (i) evaluate the efficacy of Trauma Management Therapy (TMT) for treating PTSD-related interpersonal dysfunction, as well as PTSD-related fear and anxiety, and (ii) evaluate neural mediators of clinical improvements associated with TMT.

This work will provide insights into the mechanisms by which treatments may lead to improvements in social functioning, informing both the biological basis of psychotherapy and the development and refinement of alternative therapeutic interventions targeting social impairments.

Treatment seeking Veterans with PTSD will be randomized to one of two treatments: (i) Trauma Management Therapy, consisting of 12 sessions of individualized exposure therapy followed by 24 sessions of group-based social and emotional rehabilitation, or (ii) Exposure + Comparison Treatment Group consisting of 12 sessions of individualized exposure therapy followed by 24 sessions of group-based psychotherapy. Veterans enrolled in both the TMT and EXP+GRP arms will undergo functional neuroimaging as they engage in an emotional image viewing task, as well as two social interaction tasks. Neurobehavioral assessments will be made prior to and following completion of treatment.

02

Conditions studied

  • PTSD

Keywords

  • PTSD
  • neuroimaging
  • fMRI
  • veterans
  • exposure therapy
  • treatment
03

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Male and female veterans of all ethnicities
  • Meet diagnostic criteria for post-traumatic stress disorder (assessed by study staff)
  • Fluent in English
  • Able to see computer display clearly
  • Able to provide informed consent
  • Able to follow written or verbal instructions

Exclusion criteria

Exclusion Criteria:

  • history of seizures
  • history of stroke
  • Cushing's syndrome
  • history of moderate to severe traumatic brain injury
  • electroconvulsive therapy within 5 years
  • history of chemotherapy for cancer
  • contraindications to fMRI
  • pregnancy
  • diagnosis of schizophrenia, schizoaffective disorder, delusional disorder and/or organic psychosis
04

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Trauma Management Therapy

    Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.

    Other: Trauma Management Therapy

  • Active comparator
    Exposure Therapy with Psychoeducation

    Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.

    Other: Exposure Therapy with Psychotherapy group

Interventions

  • OtherTrauma Management Therapy

    Trauma Management Therapy (TMT) consists of a combination of 12 sessions of individualized exposure therapy and 24 sessions of group-based social and emotion rehabilitation.

    Also known as: TMT

  • OtherExposure Therapy with Psychotherapy group

    Exposure Therapy with Psychoeducation (EXP+EDU) consists of a combination of 12 sessions of individualized exposure therapy and 24 session of group-based psychoeducation.

    Also known as: EXP+GRP

05

What researchers measure

Primary outcomes

  1. Change in Clinician-Administered PTSD Scale for DSM-5

    The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al. 2013; 2017) is a 20 item semi-structured instrument for the diagnosis and assessment of severity of posttraumatic stress disorder (PTSD). Each DSM-5 item is rated on a 0 (absent) to 4 (extreme/incapacitating) scale, and total score is calculated by summing severity scores across items. Total CAPS-5 severity can range from 0 to 80. \[edited 2/24/24: Higher scores mean a worse outcome.\]

    Time frame: CAPS-5 will be assessed at two time-points per participant: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).

  2. Change in Social Adjustment Scale - Self-Report

    The Social Adjustment Scale (SAS; Weissman \& Bothwell, 1976) is a 54 item self-report measure that assesses social adjustment in six social areas of functioning including work, social and leisure activities, extended family, marital, parental, and family. Each item is rated on a five point scale, and within each of domain items are averaged. Thus, scores in each domain can range between 1 (high social adjustment) and 5 (low social adjustment). \[edited 2/24/24 Higher scores mean a worse outcome.\]

    Time frame: SAS will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).

  3. Change in PTSD Checklist for DSM-5

    The PTSD Checklist for DSM-5 (PCL-5; Weathers et al., 2013; Bovin et al., 2016) is a 20 item self-report measure assessing DSM-5 PTSD symptom severity. Each DSM-5 item is rated on a 0 (absent) to 4 (extreme/incapacitating) scale, and total score is calculated by summing severity scores across items. Total CAPS-5 severity can range from 0 to 80. Higher scores mean a worse outcome.

    Time frame: The PCL-5 will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).

Secondary outcomes

  1. Change in Aggression Questionnaire

    Change in Aggression Questionnaire (AQ; Buss \& Warren, 2000) is a 34 item self-report measure that assesses severity of self-perceived aggression and anger. Each item is rated on a 1 (Not at all like me) to 5 (Completely like me) scale, and scores of all items are summed. Scores can range from 34 to 170. Higher scores mean a worse outcome.

    Time frame: AQ will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).

  2. Change in Interpersonal Trust Scale

    Change in Interpersonal Trust Scale (ITS; Rotter, 1967) is a 25 item self-report measure that assesses trust within relationships. Each item is rated on a 1 (low trust) to 5 (high trust) scale, and total scores can range from 25 to 125. \[edited 2/24/24: Higher scores mean a better outcome.\]

    Time frame: ITS will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).

06

Results

Posted Jul 1, 2024

Participant flow

Participant flow — Overall Study
MilestoneTrauma Management TherapyExposure Therapy With Psychoeducation
Started4029
Completed2924
Not completed115

Outcome measures

PrimaryChange in Clinician-Administered PTSD Scale for DSM-5

The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5; Weathers et al. 2013; 2017) is a 20 item semi-structured instrument for the diagnosis and assessment of severity of posttraumatic stress disorder (PTSD). Each DSM-5 item is rated on a 0 (absent) to 4 (extreme/incapacitating) scale, and total score is calculated by summing severity scores across items. Total CAPS-5 severity can range from 0 to 80. \[edited 2/24/24: Higher scores mean a worse outcome.\]

Time frame:
CAPS-5 will be assessed at two time-points per participant: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).
Reported as:
Mean · score on a scale
Change in Clinician-Administered PTSD Scale for DSM-5
score on a scaleTrauma Management TherapyExposure Therapy With Psychoeducation
Pre-treatment38.39 ± 2.83435835.67 ± 1.76075
Post-treatment27.15 ± 4.32471529.31 ± 2.813394
Statistical analysis
  • Trauma Management Therapy vs Exposure Therapy With Psychoeducation · Regression, Linear · p = 0.4154 (This P value is the interaction term between Visit and Treatment.) · Slope: 5.3846This is the beta value for the interaction term between Visit and Treatment.
PrimaryChange in Social Adjustment Scale - Self-Report

The Social Adjustment Scale (SAS; Weissman \& Bothwell, 1976) is a 54 item self-report measure that assesses social adjustment in six social areas of functioning including work, social and leisure activities, extended family, marital, parental, and family. Each item is rated on a five point scale, and within each of domain items are averaged. Thus, scores in each domain can range between 1 (high social adjustment) and 5 (low social adjustment). \[edited 2/24/24 Higher scores mean a worse outcome.\]

Time frame:
SAS will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).
Reported as:
Mean · mean score on a scale
Change in Social Adjustment Scale - Self-Report
mean score on a scaleTrauma Management TherapyExposure Therapy With Psychoeducation
Pre-treatment2.855 ± 0.13214213.168 ± 0.1061295
Post-treatment2.953 ± 0.18696823.289 ± 0.125691
Statistical analysis
  • Trauma Management Therapy vs Exposure Therapy With Psychoeducation · Regression, Linear · p = 0.4636 (This P value is the interaction term between Visit and Treatment.) · Slope: 0.267397This is the beta value for the interaction term between Visit and Treatment.
PrimaryChange in PTSD Checklist for DSM-5

The PTSD Checklist for DSM-5 (PCL-5; Weathers et al., 2013; Bovin et al., 2016) is a 20 item self-report measure assessing DSM-5 PTSD symptom severity. Each DSM-5 item is rated on a 0 (absent) to 4 (extreme/incapacitating) scale, and total score is calculated by summing severity scores across items. Total CAPS-5 severity can range from 0 to 80. Higher scores mean a worse outcome.

Time frame:
The PCL-5 will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).
Reported as:
Mean · score on a scale
Change in PTSD Checklist for DSM-5
score on a scaleTrauma Management TherapyExposure Therapy With Psychoeducation
Pre-treatment53.66 ± 2.59417556.92 ± 2.917909
Post-treatment40.04 ± 3.61081346.53 ± 4.15784
Statistical analysis
  • Trauma Management Therapy vs Exposure Therapy With Psychoeducation · Regression, Linear · p = 0.735129 (This P value is the interaction term between Visit and Treatment.) · Slope: 2.3355This is the beta value for the interaction term between Visit and Treatment.
SecondaryChange in Aggression Questionnaire

Change in Aggression Questionnaire (AQ; Buss \& Warren, 2000) is a 34 item self-report measure that assesses severity of self-perceived aggression and anger. Each item is rated on a 1 (Not at all like me) to 5 (Completely like me) scale, and scores of all items are summed. Scores can range from 34 to 170. Higher scores mean a worse outcome.

Time frame:
AQ will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).
Reported as:
Mean · score on a scale
Change in Aggression Questionnaire
score on a scaleTrauma Management TherapyExposure Therapy With Psychoeducation
Pre-treatment59 ± 1.8389664.62 ± 1.715036
Post-treatment58.92 ± 2.06674662.18 ± 3.193785
Statistical analysis
  • Trauma Management Therapy vs Exposure Therapy With Psychoeducation · Regression, Linear · p = 0.580 (This P value is the interaction term between Visit and Treatment.) · Slope: -2.64908This is the beta value for the interaction term between Visit and Treatment.
SecondaryChange in Interpersonal Trust Scale

Change in Interpersonal Trust Scale (ITS; Rotter, 1967) is a 25 item self-report measure that assesses trust within relationships. Each item is rated on a 1 (low trust) to 5 (high trust) scale, and total scores can range from 25 to 125. \[edited 2/24/24: Higher scores mean a better outcome.\]

Time frame:
ITS will be assessed at two time-points: before starting treatment i.e. pre-treatment (week 0) and at completion of treatment, i.e. post-treatment (week 8).
Reported as:
Mean · score on a scale
Change in Interpersonal Trust Scale
score on a scaleTrauma Management TherapyExposure Therapy With Psychoeducation
Pre-treatment60.21 ± 2.26690757.54 ± 1.917671
Post-treatment63.33 ± 2.49177460.41 ± 4.027533
Statistical analysis
  • Trauma Management Therapy vs Exposure Therapy With Psychoeducation · Regression, Linear · p = 0.808 (This P value is the interaction term between Visit and Treatment.) · Slope: 1.3946This is the beta value for the interaction term between Visit and Treatment.

Adverse events

Collected over 7 months, 3 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trauma Management Therapy2/40 (5%)1/40 (2.5%)0/40 (0%)
Exposure Therapy With Psychoeducation0/29 (0%)1/29 (3.4%)0/29 (0%)
Most frequent serious events
Most frequent serious events
EventTrauma Management TherapyExposure Therapy With Psychoeducation
Syncopal episodeCardiac disorders0/401/29
Psychiatric hospitalizationPsychiatric disorders1/400/29

Baseline characteristics

Treatment seeking Veterans with Post-Traumatic Stress Disorder (PTSD) assigned to each treatment group

Age, Continuous
Age, Continuous(years)Trauma Management TherapyExposure Therapy With PsychoeducationTotal
Mean51.65 ± 9.4043.83 ± 10.3548.36 ± 10.49
Sex: Female, Male
Sex: Female, Male(Participants)Trauma Management TherapyExposure Therapy With PsychoeducationTotal
Female12820
Male282149
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trauma Management TherapyExposure Therapy With PsychoeducationTotal
Hispanic or Latino235
Not Hispanic or Latino382664
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trauma Management TherapyExposure Therapy With PsychoeducationTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander101
Black or African American17825
White191938
More than one race213
Unknown or Not Reported112
07

Study locations

1 site
  • Salem VA Medical Center, Salem, VA
    Salem, Virginia 24153, United States
08

References and documents

Study documents

  • Study protocol · Jul 11, 2022
  • Statistical analysis plan · Jun 1, 2023
  • Informed consent form · Dec 6, 2021

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Registry details

Key details

Study ID
NCT03449576
Lead sponsor
VA Office of Research and Development
Responsible party
Sponsor
First posted
Feb 28, 2018
Start date
Jan 1, 2019
Primary completion
Jul 1, 2022
Completion
Jul 1, 2022
Results posted
Jul 1, 2024
Last update
Jul 24, 2024

Study contacts

Brooks King-Casas, PhD
principal investigator · Salem VA Medical Center, Salem, VA

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion